论文部分内容阅读
蛋白激酶抑制剂ｓｔａｕｒｏｓｐｏｒｉｎｅ５ｎｇ·ｍｌ￣（－１）阻断人胚肺２ＢＳ细胞于Ｇ＿１／Ｓ边界，而不影响人胃癌ＢＧＣ－８２３细胞的周期运行。细胞周期时相特异药物阿霉素、阿糖胞苦或博莱霉素Ａ＿５与ｓｔａｕｒｏｓｐｏｒｉｎｅ合用，２ＢＳ细胞和ＢＧＣ－８２３细胞的ＩＣ＿（５０）均发生改变，显示低剂量ｓｔａｕｒｏｓｐｏｒｉｎｅ增强抗癌药对肿瘤细胞的杀伤。用谷胱甘肽（ＧＳＨ）的荧光探针ｍＢＣＬ测定不同细胞周期时相的ＧＳＨ，发现ｓｔａｕｒｏｓｐｏｒｉｎｅ使２ＢＳ细胞中ＧＳＨ含量显著增高，而使ＢＧＣ－８２３细胞中ＧＳＨ含量显著下降。Ｓｔａｕｒｏｓｐｏｒｉｎｅ对正常和肿瘤细胞周期行进及胞内ＧＳＨ水平的不同影响，可能是它增强抗癌药物对肿瘤细胞杀伤作用的原因。
The protein kinase inhibitor staurosporine (5ng · ml -1) blocked the human embryonic lung 2BS cells at the G 1 / S boundary without affecting the cycle operation of BGC-823 cells. Cell cycle phase specific drugs doxorubicin, cytarabine or bleomycin A_5 combined with staurosporine, 2BS cells and BGC-823 cells IC50 (50) were changed, showing that low doses of staurosporine enhance anti-cancer drugs on the tumor Cell killing. GSH was determined by glutathione (GSH) fluorescent probe mBCL at different cell cycle phases. The results showed that staurosporine significantly increased GSH content in 2BS cells and significantly decreased GSH content in BGC-823 cells. The different effects of Staurosporine on normal and tumor cell cycle progression and intracellular GSH levels may be the reason that it enhances the killing effect of anticancer drugs on tumor cells.